FNA
FNA, or FNA Pharma Consulting, is a prominent player in the pharmaceutical consulting industry, headquartered in the United States. Founded in 2010, the company has established itself as a trusted partner for pharmaceutical and biotechnology firms, offering expert guidance in regulatory affairs, clinical development, and market access strategies. With a strong operational presence across North America and Europe, FNA is renowned for its tailored solutions that address the unique challenges faced by its clients. The firm’s core services include regulatory submissions, clinical trial management, and strategic market positioning, all designed to enhance product development and commercial success. FNA's commitment to excellence has earned it a solid reputation, making it a go-to resource for companies seeking to navigate the complexities of the pharmaceutical landscape.
DitchCarbon Score
How does FNA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
FNA's score of 37 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
FNA's reported carbon emissions
In 2023, FNA reported total carbon emissions of approximately 4,487,000 kg CO2e, a decrease from about 5,912,000 kg CO2e in 2022. The emissions breakdown for 2023 includes about 588,000 kg CO2e from Scope 1 and approximately 3,899,000 kg CO2e from Scope 2. This reflects a significant reduction in total emissions compared to previous years, where emissions were about 4,675,000 kg CO2e in 2021 and approximately 4,878,000 kg CO2e in 2020. FNA's emissions data is cascaded from its parent company, Paragon 28, Inc., with further influence from Zimmer Biomet Holdings, Inc. This corporate relationship may impact FNA's climate commitments and reporting practices. Despite the reductions, FNA has not established specific science-based targets (SBTi) or documented reduction initiatives. The absence of Scope 3 emissions data indicates a potential area for future focus. Overall, FNA's commitment to reducing its carbon footprint is evident through its decreasing emissions trend, although further transparency and targets would enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 540,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 4,338,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
FNA is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
